{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastro-esophageal+Cancer&page=6", "query": { "condition": "Gastro-esophageal Cancer", "page": 6 }, "page_size": 10 }, "pagination": { "page": 6, "page_size": 10, "total_count": 472, "total_pages": 48, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastro-esophageal+Cancer&page=7&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastro-esophageal+Cancer&page=5&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-23T14:50:08.786Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01249443", "title": "Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infection", "Recurrent Anal Cancer", "Recurrent Breast Cancer", "Recurrent Esophageal Cancer", "Recurrent Gastric Cancer", "Recurrent Metastatic Squamous Neck Cancer With Occult Primary", "Recurrent Non-small Cell Lung Cancer", "Recurrent Ovarian Epithelial Cancer", "Recurrent Salivary Gland Cancer", "Recurrent Squamous Cell Carcinoma of the Hypopharynx", "Recurrent Squamous Cell Carcinoma of the Larynx", "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity", "Recurrent Squamous Cell Carcinoma of the Nasopharynx", "Recurrent Squamous Cell Carcinoma of the Oropharynx", "Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Recurrent Verrucous Carcinoma of the Larynx", "Recurrent Verrucous Carcinoma of the Oral Cavity", "Salivary Gland Squamous Cell Carcinoma", "Stage IV Anal Cancer", "Stage IV Breast Cancer", "Stage IV Esophageal Cancer", "Stage IV Gastric Cancer", "Stage IV Non-small Cell Lung Cancer", "Stage IV Ovarian Epithelial Cancer", "Stage IV Salivary Gland Cancer", "Stage IV Squamous Cell Carcinoma of the Hypopharynx", "Stage IV Squamous Cell Carcinoma of the Larynx", "Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IV Squamous Cell Carcinoma of the Nasopharynx", "Stage IV Squamous Cell Carcinoma of the Oropharynx", "Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage IV Verrucous Carcinoma of the Larynx", "Stage IV Verrucous Carcinoma of the Oral Cavity", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "vorinostat", "type": "DRUG" }, { "name": "diagnostic laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "AIDS Malignancy Consortium", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2013-11", "completion_date": "2017-12", "has_results": false, "last_update_posted_date": "2020-07-29", "last_synced_at": "2026-10-23T14:50:08.786Z", "location_count": 10, "location_summary": "La Jolla, California • Los Angeles, California • Washington D.C., District of Columbia + 7 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01249443" }, { "nct_id": "NCT07781852", "title": "Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Bladder Cancer", "Glioma", "Glioblastoma (GBM)", "Breast Cancer", "Colorectal Cancer", "Esophageal Cancer", "Gastric Cancer (GC)", "Pharynx Cancer", "Oral Cavity Cancer", "Kidney Cancer", "Liver Cancer", "Lung Cancer (NSCLC)", "Ovarian Cancer", "Pancreatic Cancer", "PDAC - Pancreatic Ductal Adenocarcinoma", "Prostate Cancer" ], "interventions": [ { "name": "[64Cu]CM500", "type": "DRUG" }, { "name": "[68Ga]CM500", "type": "DRUG" }, { "name": "PET/MR", "type": "DEVICE" }, { "name": "PET/CT", "type": "DEVICE" }, { "name": "Blood Collection", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "DEVICE", "PROCEDURE" ], "sponsor": "Lumina Pharmaceuticals Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2026-09-01", "completion_date": "2027-09-01", "has_results": false, "last_update_posted_date": "2026-08-28", "last_synced_at": "2026-10-23T14:50:08.786Z", "location_count": 3, "location_summary": "Boston, Massachusetts • Grand Rapids, Michigan • New York, New York", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07781852" }, { "nct_id": "NCT07432295", "title": "Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Tumor", "Advanced Cancer", "Metastatic Cancer", "Gastric Cancer", "Gastroesophageal Junction Carcinoma", "Esophageal Adenocarcinoma" ], "interventions": [ { "name": "Givastomig", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "5Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "I-Mab Biopharma US Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 180, "start_date": "2026-02-11", "completion_date": "2030-08", "has_results": false, "last_update_posted_date": "2026-05-14", "last_synced_at": "2026-10-23T14:50:08.786Z", "location_count": 3, "location_summary": "Goodyear, Arizona • Duarte, California • Boston, Massachusetts", "locations": [ { "city": "Goodyear", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07432295" }, { "nct_id": "NCT07675967", "title": "Clonal Hematopoiesis Chemotherapy and Radiation Effects Study", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Lung Cancer (Diagnosis)", "Osteochondroma", "Spitz Nevus", "Solid Cancers", "Breast Cancer", "Gastric (Stomach) Cancer", "Colorectal (Colon or Rectal) Cancer", "Sarcoma", "Ovarian Adenocarcinoma", "Uterine Adenocarcinoma", "Endometrial Adenocarcinoma", "Esophageal Adenocarcinoma", "Head and Neck Cancer", "Therapy-Related Acute Myeloid Leukemia", "Therapy-Related MDS", "Clonal Hematopoiesis of Indeterminate Potential (CHIP)", "Clonal Cytopenia of Undetermined Significance" ], "interventions": [ { "name": "Samples", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5000, "start_date": "2025-04-04", "completion_date": "2035-03-31", "has_results": false, "last_update_posted_date": "2026-06-30", "last_synced_at": "2026-10-23T14:50:08.786Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07675967" }, { "nct_id": "NCT00004233", "title": "S9915 Triacetyluridine, Fluorouracil, and Leucovorin in Treating Patients With Unresectable, Locally Advanced, or Metastatic Cancer of the Esophagus or Stomach", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer", "Gastric Cancer" ], "interventions": [ { "name": "fluorouracil", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "triacetyluridine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 65, "start_date": "2001-02", "completion_date": "2007-01", "has_results": false, "last_update_posted_date": "2011-07-25", "last_synced_at": "2026-10-23T14:50:08.786Z", "location_count": 97, "location_summary": "Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 61 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004233" }, { "nct_id": "NCT06123338", "title": "A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer", "Gastric Adenocarcinoma", "HER2 Gene Mutation" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Nutrition questionnaires (optional)", "type": "OTHER" }, { "name": "stool and saliva samples (optional)", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2024-02-01", "completion_date": "2027-11-30", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-23T14:50:08.786Z", "location_count": 10, "location_summary": "Boston, Massachusetts • Basking Ridge, New Jersey • Middletown, New Jersey + 7 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06123338" }, { "nct_id": "NCT03526835", "title": "A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced/Metastatic Solid Tumors", "Colorectal Cancer", "Gastric Cancer", "Gastroesophageal-junction Cancer", "NSCLC", "HNSCC", "Head and Neck Squamous Cell Carcinoma", "Esophageal Cancer" ], "interventions": [ { "name": "MCLA-158", "type": "DRUG" }, { "name": "MCLA-158 + Pembrolizumab", "type": "COMBINATION_PRODUCT" }, { "name": "MCLA-158 + FOLFIRI", "type": "COMBINATION_PRODUCT" }, { "name": "MCLA-158 + FOLFOX", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT" ], "sponsor": "Merus B.V.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 560, "start_date": "2018-05-02", "completion_date": "2028-11", "has_results": false, "last_update_posted_date": "2026-10-20", "last_synced_at": "2026-10-23T14:50:08.786Z", "location_count": 31, "location_summary": "La Jolla, California • Los Angeles, California • San Diego, California + 25 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Lone Tree", "state": "Colorado" }, { "city": "Fort Myers", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03526835" }, { "nct_id": "NCT00096083", "title": "Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "isolated perfusion", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Delcath Systems Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 56, "start_date": "2004-09", "completion_date": "2012-08", "has_results": false, "last_update_posted_date": "2013-10-23", "last_synced_at": "2026-10-23T14:50:08.786Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00096083" }, { "nct_id": "NCT01212822", "title": "Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenocarcinoma of the Esophagus", "Adenocarcinoma of the Gastroesophageal Junction", "Diffuse Adenocarcinoma of the Stomach", "Intestinal Adenocarcinoma of the Stomach", "Mixed Adenocarcinoma of the Stomach", "Squamous Cell Carcinoma of the Esophagus", "Stage IA Esophageal Cancer", "Stage IA Gastric Cancer", "Stage IB Esophageal Cancer", "Stage IB Gastric Cancer", "Stage IIA Esophageal Cancer", "Stage IIA Gastric Cancer", "Stage IIB Esophageal Cancer", "Stage IIB Gastric Cancer", "Stage IIIA Esophageal Cancer", "Stage IIIA Gastric Cancer", "Stage IIIB Esophageal Cancer", "Stage IIIB Gastric Cancer", "Stage IIIC Esophageal Cancer", "Stage IIIC Gastric Cancer" ], "interventions": [ { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "oxaliplatin", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "therapeutic conventional surgery", "type": "PROCEDURE" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "Fox Chase Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2011-04-27", "completion_date": "2018-01-03", "has_results": true, "last_update_posted_date": "2022-09-07", "last_synced_at": "2026-10-23T14:50:08.786Z", "location_count": 3, "location_summary": "Cleveland, Ohio • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania", "locations": [ { "city": "Cleveland", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01212822" }, { "nct_id": "NCT06585488", "title": "A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Solid Tumors", "Advanced Non-squamous Non-small-cell Lung Cancer", "Advanced Colorectal Cancer", "Advanced Pancreatic Ductal Adenocarcinoma", "Advanced Gastric Cancer", "Advanced Gastroesophageal Junction Cancer", "Advanced Esophageal Adenocarcinoma" ], "interventions": [ { "name": "BGB-53038", "type": "DRUG" }, { "name": "Tislelizumab", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeOne Medicines", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2024-12-13", "completion_date": "2026-04-23", "has_results": false, "last_update_posted_date": "2026-07-08", "last_synced_at": "2026-10-23T14:50:08.786Z", "location_count": 4, "location_summary": "Los Angeles, California • Kansas City, Kansas • Baltimore, Maryland + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06585488" } ] }